ACM
SPRO icon

ADAR1 Capital Management’s Spero Therapeutics SPRO Stock Holding History

ADAR1 Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-113,839
Closed -$265K – 339
2025
Q4 		$265K Sell
113,839
-1,700
-1% -$3.95K 0.02% 215
2025
Q3 		$217K Sell
115,539
-28,378
-20% -$62.4K 0.02% 177
2025
Q2 		$417K Sell
143,917
-657,360
-82% -$946K 0.06% 126
2025
Q1 		$577K Hold
801,277
– – 0.11% 99
2024
Q4 		$825K Buy
801,277
+57,818
+8% +$68.8K 0.16% 89
2024
Q3 		$996K Sell
743,459
-175,470
-19% -$235K 0.16% 78
2024
Q2 		$1.19M Sell
918,929
-8,000
-0.9% -$12.1K 0.23% 60
2024
Q1 		$1.59M Sell
926,929
-140,782
-13% -$221K 0.36% 50
2023
Q4 		$1.57M Buy
+1,067,711
New +$1.27M 0.56% 34

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

ADAR1 Capital Management's SPRO Position: Q1 2026 in Review

ADAR1 Capital Management sold out of Spero Therapeutics (SPRO) in Q1 2026, closing a stake of 113,839 shares — an estimated $265K sold.

ADAR1 Capital Management first reported a position in SPRO in Q4 2023 and held it in 9 quarters. The position peaked at $1.59M in Q1 2024. 50 funds tracked by Wall St. Rank hold SPRO as of Q1 2026.

  • ADAR1 Capital Management reported no remaining Spero Therapeutics position as of Q1 2026 after selling out during the quarter.
  • ADAR1 Capital Management sold 113,839 Spero Therapeutics shares in Q1 2026, an estimated $265K.
  • ADAR1 Capital Management first reported a position in Spero Therapeutics in Q4 2023 and held it in 9 quarters.
  • ADAR1 Capital Management's Spero Therapeutics position peaked at $1.59M in Q1 2024.
  • 50 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2026.

Based on ADAR1 Capital Management's 13F filing for Q1 2026, filed 18 May 2026.